Vir's over­haul brings an end to most vi­rol­o­gy work — and a be­gin­ning with can­cer

Last year’s lay­offs were just the start for Vir Biotech­nol­o­gy.

The com­pa­ny is now shift­ing the di­rec­tion of its clin­i­cal and cor­po­rate op­er­a­tions by pri­or­i­tiz­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER